Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Virtual Booth

    Contact Supplier

    Menu

    guanidine propionate

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Regenxbio Shows Benefits of Microdystrophin in Duchenne Gene
    Regenxbio Shows Benefits of Microdystrophin in Duchenne Gene

    11 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenxbio-announces-publication-of-preclinical-results-demonstrating-functional-benefits-of-novel-microdystrophin-construct-in-rgx-202-investigational-gene-therapy-for-duchenne-muscular-dystrophy-302502606.html

    PR NEWSWIRE
    11 Jul 2025
    Share Share
    Inspirna Partners with Merck to Accelerate Global Development of Ompenaclid
    Inspirna Partners with Merck to Accelerate Global Development of Ompenaclid

    04 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240104830287/en

    BUSINESSWIRE
    04 Jan 2024
    Share Share
    Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid
    Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid

    23 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231023708620/en

    BUSINESSWIRE
    23 Oct 2023
    Share Share
    Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid
    Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid

    16 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231016553717/en

    BUSINESSWIRE
    16 Oct 2023
    Share Share